Adds valuation target in paragraph 1, details on IPO throughout
Jan 21 (Reuters) - China-based Ascentage Pharma 6855.HK said on Tuesday it was targeting a valuation of $1.75 billion in its initial public offering in the United States.
Ascentage, backed by Japan's biggest drugmaker Takeda Pharmaceutical 4502.T, is seeking $149 million by offering about 7.3 million American depositary shares at $20.34 each.
J.P.Morgan and Citigroup are the underwriters for the offering.
Ascentage will list on the Nasdaq under the symbol "AAPG".
(Reporting by Arasu Kannagi Basil in Bengaluru; Editing by Shounak Dasgupta)
((ArasuKannagi.Basil@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.